Following an inspiring stay at the Gene Center Munich and a short postdoc at the University of Ulm, I returned to Munich to head a research group focusing on preclinical research in neuromuscular disorders. There I started applying viral vectors for therapeutic purposes. Their inherent potential to provide a curative treatment for diseases like duchenne muscular dystrophy is inspiring. With SIRION Biotech we began to develop viral vector technologies for clinical uses. Today the scope of SIRION’s activities includes viral vector-based vaccines, and the generation of vectors for gene and cell therapies. SIRION Biotech’s flagship technology LentiBOOST® improves manufacturing for CAR-T and hematopoietic stem cell-based therapeutics and enabled the approval of a stem cell product to treat anemias. In the future SIRION will focus on the development of next generation gene delivery vectors for more efficient and affordable treatments.